Shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five analysts that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $16.95.
Several research firms have recently weighed in on RDY. Wall Street Zen raised shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Hsbc Global Res raised shares of Dr. Reddy's Laboratories from a "hold" rating to a "strong-buy" rating in a research note on Thursday, June 5th. HSBC raised shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating and lifted their price target for the company from $14.44 to $16.90 in a research note on Thursday, June 5th. Finally, Zacks Research raised shares of Dr. Reddy's Laboratories from a "strong sell" rating to a "hold" rating in a research note on Friday, August 15th.
Read Our Latest Stock Analysis on Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Trading Up 0.7%
Shares of RDY stock traded up $0.0950 on Tuesday, reaching $14.5150. 1,032,160 shares of the company's stock were exchanged, compared to its average volume of 1,339,768. Dr. Reddy's Laboratories has a 52 week low of $12.26 and a 52 week high of $16.77. The company has a current ratio of 1.89, a quick ratio of 1.36 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $12.12 billion, a PE ratio of 21.99, a P/E/G ratio of 5.84 and a beta of 0.29. The company's fifty day simple moving average is $14.60 and its 200 day simple moving average is $14.03.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.02. Dr. Reddy's Laboratories had a return on equity of 17.25% and a net margin of 16.99%.The firm had revenue of $988.82 million during the quarter, compared to analyst estimates of $88.27 billion. As a group, analysts forecast that Dr. Reddy's Laboratories will post 0.8 EPS for the current year.
Institutional Trading of Dr. Reddy's Laboratories
Hedge funds have recently bought and sold shares of the stock. Costello Asset Management INC purchased a new stake in Dr. Reddy's Laboratories during the first quarter worth $26,000. Westside Investment Management Inc. purchased a new stake in Dr. Reddy's Laboratories during the second quarter worth $35,000. Legacy Advisors LLC purchased a new stake in Dr. Reddy's Laboratories during the first quarter worth $41,000. EverSource Wealth Advisors LLC lifted its holdings in Dr. Reddy's Laboratories by 71.7% during the second quarter. EverSource Wealth Advisors LLC now owns 3,100 shares of the company's stock worth $47,000 after buying an additional 1,294 shares during the period. Finally, Tower Research Capital LLC TRC lifted its holdings in Dr. Reddy's Laboratories by 623.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,032 shares of the company's stock worth $48,000 after buying an additional 2,613 shares during the period. Hedge funds and other institutional investors own 3.85% of the company's stock.
Dr. Reddy's Laboratories Company Profile
(
Get Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Further Reading
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
